Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 20...
March 02 2020 - 8:30AM
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will release financial results and business updates for the
fourth quarter and fiscal year ended December 31, 2019 on Monday,
March 9, 2020. The Company will host a webcast and conference call
that day at 8:30 a.m. Eastern Time to discuss these results and
updates.
The live call may be accessed by dialing (877) 312-5845
(domestic) or (765) 507-2618 (international) and referring to
conference ID number 7176196. A live webcast of the conference call
will be available online in the Investors and Media section of the
Company’s website at ir.minervaneurosciences.com. The archived
webcast will be available on the Company’s website beginning
approximately two hours after the event for 30 days.
The live webcast can be accessed under “Events and
Presentations” in the Investors and Media section of Minerva’s
website at ir.minervaneurosciences.com. The archived webcast will
be available on the website beginning approximately two hours after
the event for 90 days.
About Minerva Neurosciences
Minerva’s proprietary compounds include: roluperidone (MIN-101),
in clinical development for schizophrenia; seltorexant (MIN-202 or
JNJ-42847922), in clinical development for insomnia and major
depressive disorder (MDD); and MIN-301, in pre-clinical development
for Parkinson’s disease. Minerva’s common stock is listed on the
NASDAQ Global Market under the symbol “NERV.” For more information,
please visit www.minervaneurosciences.com.
Contact:
William B. BoniVP, Investor RelationsCorp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Sep 2023 to Sep 2024